Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9–14 years: results of the long-term extension of the DoRIS randomised trial

UK Department of Health and Social Care, UK Foreign, Commonwealth & Development Office, Global Challenges Research Fund, UK Medical Research Council, and the Wellcome Trust through the Joint Global Health Trials Scheme; Bill & Melinda Gates Foundation.

Authors

Institutions

Publication Details

Journal
The Lancet Global Health
Published
2025-01-29
DOI
https://doi.org/10.1016/s2214-109x(24)00477-7
Citations
15
Primary Topic
Cervical Cancer and HPV Research
Type
article
Field-Weighted Citation Impact
20.31

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9–14 years: results of the long-term extension of the DoRIS randomised trial

Philippe Mayaud, Sílvia de Sanjosé, Hilary Whitworth, Paul Mutani et al.
15 citations
The Lancet Global Health
Cervical Cancer and HPV Research
20.31
article

Durability of immunogenicity at 5 years after a single dose of human papillomavirus vaccine compared with two doses in Tanzanian girls aged 9–14 years: results of the long-term extension of the DoRIS randomised trial

Philippe Mayaud, Sílvia de Sanjosé, Hilary Whitworth, Paul Mutani, Joakim Dillner, Saidi Kapiga, Rebecca Wiggins, Troy J. Kemp, Jackton Indangasi, G.H. Constantine, Nicholas E. Connor, Lígia A. Pinto, Miguel Ángel Pavón, John Changalucha, Ramadhan Hashim, Brett Lowe, Beatrice Kamala, Charles Lacey, Richard Hayes, David Mwanzalima, Caroline Maxwell, Devis Mmbando, Deborah Watson-Jones, Kathy Baisley
article en
15 citations

Abstract

UK Department of Health and Social Care, UK Foreign, Commonwealth & Development Office, Global Challenges Research Fund, UK Medical Research Council, and the Wellcome Trust through the Joint Global Health Trials Scheme; Bill & Melinda Gates Foundation.

The Lancet Global HealthVol. 13(2)
Leidos (United States) (US), Karolinska Institutet (SE), London School of Hygiene & Tropical Medicine (GB), Frederick National Laboratory for Cancer Research (US), Mwanza Intervention Trials Unit (TZ), National Institute for Medical Research (TZ), Leidos Biomedical Research Inc. (United States), University of York (GB), Hull York Medical School (GB)
Bill and Melinda Gates Foundation, Wellcome Trust, Department of Health and Social Care, Foreign, Commonwealth and Development Office, Global Challenges Research Fund, Medical Research Council
Good health and well-being
Openalex Percentile: Top 1%
Cervical Cancer and HPV Research
20.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.